IRL1009

IRL1009 is a **preclinical small-molecule CNS drug candidate** from **IRLAB Therapeutics** for neurodegenerative disease- and aging-associated decline in **cognition, mental function, and motor performance**, with particular relevance to Parkinson's disease-related impairment. It was discovered using IRLAB's **Integrative Screening Process** platform within the **P001** research program and has been described as a **backup compound to IRL942** with similar pharmacologic effects. Available preclinical information indicates that IRL1009 **increases nerve cell signaling** and **improves cognition in behavioral studies**, but its precise molecular target and binding pharmacology have not been publicly defined in the provided materials. The program had reached late preclinical preparation for first-in-human testing, with composition-of-matter patent protection reported in the United States and Europe.